A controlled double-blind trial was conducted to evaluate the efficacy of adalimumab in inducing and maintaining clincial remission in 494 patients with moderate-to-severe ulcerative colitis who received concurrent conventional therapy (oral corticosteriods or immunosuppressants). Primary end points were remission at weeks 8 and 52. Rates of clinical remission were significantly greater in the adalimumab treatment group at both time points when compared with the placebo-treated group. Adalimumab was safe, well-tolerated and effective in patients who did not have an adequate response to conventional therapy.
ORIGINAL RESEARCH PAPER
Sandborn, W. J. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology doi:10.1053/j.gastro.2011.10.032
Rights and permissions
About this article
Cite this article
Adalimumab promotes clinical remission in patients with ulcerative colitis. Nat Rev Gastroenterol Hepatol 9, 6 (2012). https://doi.org/10.1038/nrgastro.2011.234
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.234